Health Economics›Small cell lung cancer›Extensive stage maintenance after first-line therapy

Extensive stage maintenance after first-line therapy

Small cell lung cancer · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 471 692	84d	~3.8 mo	~14.2 mo	~2	~R 943 384 PFS proxy · indirect	11
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~3.7 mo	~19.6 mo	~6	~R 343 479 PFS proxy · indirect	2
Sunitinib monotherapy Variant #05	—	R 33 433	28d	3.7 mo	—	5	R 167 165 PFS proxy	1
Observation Partial	—	—	—	2.2 mo	—	—	—	2
Placebo Partial	—	—	—	—	9.7 mo	—	—	5

5 of 5 regimens shown